90/013,866BETA-LACTAMASE INHIBITORS9,376,454Closed

Status

Reexamination Certificate Issued

Filed

Dec 5, 2016

Last Updated

Nov 28, 2017

Art Unit

3991

Requester (Patent Owner)Inferred

Venatorx Pharmaceuticals Inc.

Requested By

Patent Owner

Sector (CPC)

CChemistry & Materials
C07Organic Chemistry
C07FAcyclic Organometallic

USPC

514Drug, Bio-Affecting And Body Treating Compositions

Reexam History (32 events)

Nov 29, 2017CCRDYApplication ready for PDX access by participating foreign offices
Nov 28, 2017REEXInput Issue Number and Issue Date for Reexamination
Oct 15, 2017RXPUBSReexam Forwarded to Office of Publications
Aug 24, 2017MRNRCRX - Mail Notice of Intent to Issue a Reexam Certificate
Jul 28, 2017BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)
Jul 19, 2017RXSA..Supplemental Response after Non-Final Rejection
Jul 18, 2017RXLITSRReexam Litigation Search Conducted
Jul 17, 2017RXLITSRReexam Litigation Search Conducted
May 11, 2017RXA...Response after Non-Final Action
Apr 20, 2017MR.NFRX - Mail Reexam Non-Final Action
Mar 15, 2017RXFWDXDate Forwarded to Examiner
Jan 31, 2017NRX.Notice of Reexam Published in Official Gazette
Jan 11, 2017RXWVSTWaiver of owners statement in ex parte
Jan 11, 2017RXA.PEPre-Examination Amendment
Jan 9, 2017MREXORX - Mail Ex Parte Request for Reexamination Granted
Dec 29, 2016MRPWPRX - Mail Pilot Waiver Program - Ex Parte Interview Summary
Dec 27, 2016IDSCInformation Disclosure Statement considered
Dec 22, 2016RXLITSRReexam Litigation Search Conducted
Dec 21, 2016DOCKCase Docketed to Examiner in GAU
Dec 20, 2016MRXNReexamination Formalities Notice Mailed
Dec 20, 2016MRXNReexamination Formalities Notice Mailed
Dec 19, 2016SMALApplicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27
Dec 19, 2016RXPCOMCompletion of Preprocessing - Released to Assigned GAU
Dec 19, 2016FTFIFITF set to NO - revise initial setting
Dec 18, 2016RXTTLRPTTitle Report
Dec 18, 2016RXNREQFDNotice of reexamination request filing date
Dec 18, 2016RXNREQAUNotice of assignment of reexamination request
Nov 29, 2016WIDSInformation Disclosure Statement (IDS) Filed
Nov 29, 2016RXOSUBReceipt of Original Ex Parte Reexam Request
Nov 29, 2016RXIDS.Information Disclosure Statement Filed
Nov 29, 2016RXA.PEPre-Examination Amendment
Nov 29, 2016BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)

Prosecution, PTAB & CAFC

PTAB Proceedings (IPR, PGR, CBM, DER)

None found

Federal Circuit (CAFC)

None found

Terminal Disclaimer

Filed — ApprovedNov 23, 2015

Prosecution History

DateCodeDescription
Nov 23, 2015P574PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED
Nov 23, 2015DISTTerminal Disclaimer Filed

Maintenance Fees

Grant
Jun 28, 2016
3.5-yr
Dec 28, 2019
Paid Dec 30, 2019
7.5-yr
Dec 28, 2023
11.5-yr
Dec 28, 2027
Expiry
Apr 22, 2035

Entity Status

Large Entity

Expires

Apr 22, 2035 (9.1 yr remaining)

Other

USPTO Event: Expire PatentUSPTO Event: Maintenance Fee Reminder Mailed

Assignments

20142015201620172018201920202021FiledCHRISTOPHER J. BURNSDENIS DAIGLERANDY W. JACKSONBIN LIUDANIEL MCGARRYDANIEL C. PEVEARROBERT E. LEE TROUTVENATORX PHARMACEUTICALS, INC.U.S. GOVERNMENT U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) NATIONAL INSTITUTES OF HEALTH (NIH)
AssignmentReel/Frame: 035473/0549Recorded: Apr 22, 2015

From

CHRISTOPHER J. BURNSInventor
Jan 29, 2014
DENIS DAIGLEInventor
Jan 29, 2014
RANDY W. JACKSONInventor
Jan 29, 2014
BIN LIUInventor
Jan 29, 2014
DANIEL MCGARRYInventor
Jan 29, 2014
DANIEL C. PEVEARInventor
Jan 29, 2014
ROBERT E. LEE TROUTInventor
Jan 29, 2014

To

VENATORX PHARMACEUTICALS, INC.

OtherReel/Frame: 061933/0751Recorded: Nov 14, 2022

From

VENATORX PHARMACEUTICALS INC
Dec 10, 2020

To

U.S. GOVERNMENT U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) NATIONAL INSTITUTES OF HEALTH (NIH)